Klimed MK Sp. z o.o. — Clinical Trial Site

12 Registered trials

2 Currently recruiting

Organisation

Klimed MK Sp. z o.o.

Location

Bialystok, Poland

Identifier

ORG-100045011

Address

Aleja Jana Pawla II 59/6u, 15-704, Poland

Departments

-
3016:Cardiology
cardiology department
KLIMED Marek Klimkiewicz
N/A
NA
not applicable

Clinical trials at this site (12)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting

2022-500544-38-00 Advanced Breast Cancer 5 2023-06-05
A Phase 3 Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis Recruiting

2022-500367-12-00 Dermatomyositis 5 2022-11-30
A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei… Ended

2023-508306-15-00 Alzheimer’s Disease 5 2024-06-26
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Ended

2023-503659-88-00 Obesity 5 2023-09-05
To access the effect of SCD-044 in treatment of moderate to severe atopic dermatitis Ended

2024-511615-16-00 atopic dermatitis 4 2023-08-25
A Phase 1b, 2-part, placebo-controlled study to evaluate the efficacy, safety, and PK of PF-07054894 in participants with mild to severe UC. Ended

2022-501047-32-00 ULCERATIVE COLITIS 3 2023-05-30
A Study of LY3540378 in Participants with Worsening Chronic Heart Failure with Preserved Ejection Fraction (HFpEF) Ended

2023-505902-40-00 Heart Failure with Preserved Ejection Fraction 4 2023-03-28
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease Ended

2023-507303-55-00 Alzheimer Disease 4 2020-09-30